ŘIHÁČEK, Ivan, Petr FRÁŇA, Daniel SCHWARZ, Martin PLACHÝ a Miroslav SOUČEK. THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME. In 20th European meeting on Hypertension, Oslo, 18-21.6.2010. ISSN 1473-5598. 2010.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME.
Název česky Normalizovaný smoothness index a populační RDH index losartanu a telmisartanu u pacientů s čerstvě zjištěnou hypertenzí a metabolickým syndromem
Název anglicky THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME.
Autoři ŘIHÁČEK, Ivan, Petr FRÁŇA, Daniel SCHWARZ, Martin PLACHÝ a Miroslav SOUČEK.
Vydání 20th European meeting on Hypertension, Oslo, 18-21.6.2010. 2010.
Další údaje
Originální jazyk čeština
Typ výsledku Konferenční abstrakt
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.980
Organizační jednotka Lékařská fakulta
ISSN 1473-5598
UT WoS 000283023404270
Klíčová slova česky smoothness index; RDH index; telmisartan; losartan
Klíčová slova anglicky smoothness index; RDH index; telmisartane; losartane
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnil: MUDr. Ivan Řiháček, Ph.D., učo 2313. Změněno: 17. 1. 2011 13:02.
Anotace
Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Results: systolic blood pressure(SBP)normalized smoothness index of losartane was 1,10, telmisartane 0,96, diastolic blood pressure (DBP) normalized smoothness index of losartane was 0,81, telmisartane 0,80. RHP index for SBP for losartane was 24,24,0, for telmisartane 24,24,0, for DBP for losartane 24,24,0, for telmisartane 21,15,2. Cnclusions: losartane have reasonably better homogenous effect on blood pressure than telmisartane.
Anotace anglicky
Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Results: systolic blood pressure(SBP)normalized smoothness index of losartane was 1,10, telmisartane 0,96, diastolic blood pressure (DBP) normalized smoothness index of losartane was 0,81, telmisartane 0,80. RHP index for SBP for losartane was 24,24,0, for telmisartane 24,24,0, for DBP for losartane 24,24,0, for telmisartane 21,15,2. Cnclusions: losartane have reasonably better homogenous effect on blood pressure than telmisartane.
Návaznosti
MSM0021622402, záměrNázev: Časná diagnostika a léčba kardiovaskulárních chorob
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Časná diagnostika a léčba kardiovaskulárních chorob
VytisknoutZobrazeno: 29. 3. 2024 15:47